Merck Stock Down 4% Since Q2 Results: How to Play the Stock

Key Takeaways MRK Q2 earnings beat estimates but revenues fell 2% to $15.8B hit by weaker vaccine sales.Keytruda sales rose 9% in Q2, driving growth alongside Capvaxive and Winrevair launches.MRK trades at a P/E of 8.64, below the industry average, with a pipeline of 20+ potential launches.Merck (MRK) stock has declined 4% since it announced second-quarter results on July 29 before market open. While the company’s earnings beat estimates, its sales came in line. Earnings of$ 2.13 per share declined 7% year ...